Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Farydak (panobinostat)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Secura Bio

Drug class:

HDAC inhibitor

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1	bortezomib + panobinostat Sensitive: A1 - Approval bortezomib + panobinostat Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	panobinostat Sensitive: A2 - Guideline panobinostat Sensitive : A2	panobinostat Sensitive: A2 - Guideline panobinostat Sensitive : A2
H3.3K27M	Glioma	H3.3K27M	Glioma	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3
S100A9 expression	Multiple Myeloma	S100A9 expression	Multiple Myeloma	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3
S100A8 expression	Multiple Myeloma	S100A8 expression	Multiple Myeloma	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3	bortezomib + panobinostat Resistant: C3 – Early Trials bortezomib + panobinostat Resistant : C3
ERBB3 overexpression	Triple Negative Breast Cancer	ERBB3 overexpression	Triple Negative Breast Cancer	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3	panobinostat Sensitive: C3 – Early Trials panobinostat Sensitive : C3
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D
MLL fusion	Acute Myelogenous Leukemia	MLL fusion	Acute Myelogenous Leukemia	cytarabine + azacitidine + panobinostat Sensitive: D – Preclinical cytarabine + azacitidine + panobinostat Sensitive : D	cytarabine + azacitidine + panobinostat Sensitive: D – Preclinical cytarabine + azacitidine + panobinostat Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D
ASS1 underexpression	Pancreatic Ductal Adenocarcinoma	ASS1 underexpression	Pancreatic Ductal Adenocarcinoma	panobinostat + pegargiminase Sensitive: D – Preclinical panobinostat + pegargiminase Sensitive : D	panobinostat + pegargiminase Sensitive: D – Preclinical panobinostat + pegargiminase Sensitive : D
MLL-AFF1 fusion	Acute Lymphocytic Leukemia	MLL-AFF1 fusion	Acute Lymphocytic Leukemia	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	AN2025 + panobinostat Sensitive: D – Preclinical AN2025 + panobinostat Sensitive : D	AN2025 + panobinostat Sensitive: D – Preclinical AN2025 + panobinostat Sensitive : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D	panobinostat Sensitive: D – Preclinical panobinostat Sensitive : D